Liquid Biopsy Market Size to grow by USD 1.74 Bn by 2026 with 55% of the growth to originate from North America - Technavio

2022-10-19

NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Do you know the

liquid biopsy market is expected to grow by

USD 1.74 billion at a CAGR of 18.77% during the forecast period of 2021-2026? The liquid biopsy market report offers vendor details for AccuraGen Holdings, Adaptive Biotechnologies Corp., ANGLE Plc, Bio Rad Laboratories Inc., Biocept Inc., CellMax Inc., Epigenomics AG, F. Hoffmann La Roche Ltd., GeneFirst Ltd., Guardant Health Inc., HansaBioMed Life Sciences Ltd., Illumina Inc., MDNA Lfe Sciences Inc., MDxHealth Group, and Thermo Fisher Scientific Inc. among others.

Liquid Biopsy Market Size to grow by USD 1.74 Bn by 2026 with 55% of the growth to originate from North America - Technavio

Preview

来源: PRNewswire

Technavio has announced its latest market research report titled Global Liquid Biopsy Market 2022-2026

The report further entails liquid biopsy market segmentation, including Technology(CTC and ctDNA and Exosome and RNA) and Geography(North America, Europe, Asia, and Rest of World (ROW)).

Request Free Sample Report.

Liquid Biopsy Market – Vendor Offerings

ANGLE Plc: The company offers liquid biopsy solutions that are used to inform clinicians about the patient's condition and highly capture the efficiency and purity of CTCs, under the brand name of Parsortix.

Bio-Techne Corp.: The company offers liquid biopsy that provides a simple, painless, and accurate answer to inform the prostate biopsy decision, under the brand name of ExoDx.

Biocept Inc.: The company operates through a single segment wherein it develops and commercializes proprietary circulating tumor cells and circulating tumor DNA, and assays utilizing a standard blood sample.

CIRCULOGENE: The company offers liquid biopsy solutions that combine droplet volumes of blood and the most advanced NGS to detect known tumor mutant DNA within well-characterized, well-documented, cancer-associated genes present in diagnosed cancer patients, under the brand name of CIRCULOGENE.

F. Hoffmann-La Roche Ltd.: The company offers liquid biopsy solutions that help in sample collection, polymerase chain reaction testing, and next-generation sequencing, under the brand name of Cobas.

To find additional highlights on the growth strategies adopted by vendors and their product offerings,

Download Sample Report

Liquid Biopsy Market

– Geographical analysis

North America will account for 55% of the market's growth throughout the projection period. The main markets for liquid biopsy in North America are the US and Canada. Compared to the markets in Europe and Asia, this region's market will grow more slowly.

Over the course of the forecast period, the growth of the liquid biopsy market in North America will be aided by factors such as rising demand for anti-cancer drug development, rising adoption of technologically advanced biopsy tests, aging populations, high screening costs for various cancer types, and an increase in biotechnology and pharmaceutical companies.

Buy Sample Report.

Liquid Biopsy Market

– Segment Analysis by Technology

Fast-growing technological segments are those that will grow more quickly than the total market, whereas slow-growing segments are those that will develop more slowly than the overall market. The cells that break out from the main tumor and circulate in the bloodstream are known as CTCs. At any point in the therapeutic course of treating metastatic cancer, CTCs are thought to be indications of disease progression. These tests also have a high specificity. The most used test is the ctDNA test since it is very sensitive and enables the examination of DNA methylation and sequencing.

Additionally, it enables fast and dynamic tumor progression monitoring and can lessen the diagnosis bias brought on by tumor heterogeneity. Vendors are focusing on the development of novel methods for capturing CTCs and ctDNAs to detect a vast array of cancers before the physical manifestation of symptoms and to track the progression of tumors throughout treatment.

Get a Free Sample Report.

Related Reports:

Periodontal Dental Services Market by End-user, Service, and Geography - Forecast and Analysis 2022-2026: The rise in periodontal diseases is notably driving the periodontal dental services market growth. The report extensively covers periodontal dental services market segmentation by end-user (hospitals and dental clinics), service (non-surgical and surgical), and geography (North America, Europe, Asia, and Rest of World (ROW)).

Ocular Implants Market by Product and Geography - Forecast and Analysis 2022-2026: The increasing prevalence of ophthalmic diseases is notably driving the ocular implants market growth. The report extensively covers ocular implant market segmentation by product (IOLs, corneal implants, glaucoma implants, and ocular prostheses) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Table of Content:

1 Executive Summary

2 Market Landscape

2.1 Market ecosystem

Exhibit 01: Parent market

Exhibit 02: Market characteristics

2.2 Value chain analysis

Exhibit 03: Value Chain Analysis: Healthcare supplies

3 Market Sizing

3.1 Market definition

Exhibit 04: Offerings of vendors included in the market definition

3.2 Market segment analysis

Exhibit 05: Market segments

3.3 Market size 2020

3.4 Market outlook: Forecast for 2020 - 2025

Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)

Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)

4 Five Forces Analysis

4.1 Five forces summary

Exhibit 08: Five forces analysis 2020 & 2025

4.2 Bargaining power of buyers

Exhibit 09: Bargaining power of buyers

4.3 Bargaining power of suppliers

Exhibit 10: Bargaining power of suppliers

4.4 Threat of new entrants

Exhibit 11: Threat of new entrants

4.5 Threat of substitutes

Exhibit 12: Threat of substitutes

4.6 Threat of rivalry

Exhibit 13: Threat of rivalry

4.7 Market condition

Exhibit 14: Market condition - Five forces 2020

5 Market Segmentation by Technology

5.1 Market segments

Exhibit 15: Technology - Market share 2020-2025 (%)

5.2 Comparison by Technology

Exhibit 16: Comparison by Technology

5.3 CTC and ctDNA - Market size and forecast 2020-2025

Exhibit 17: CTC and ctDNA - Market size and forecast 2020-2025 ($ million)

Exhibit 18: CTC and ctDNA - Year-over-year growth 2020-2025 (%)

5.4 Exosome and RNA - Market size and forecast 2020-2025

Exhibit 19: Exosome and RNA - Market size and forecast 2020-2025 ($ million)

Exhibit 20: Exosome and RNA - Year-over-year growth 2020-2025 (%)

5.5 Market opportunity by Technology

Exhibit 21: Market opportunity by Technology

6 Customer landscape

7 Geographic Landscape

7.1 Geographic segmentation

Exhibit 23: Market share by geography 2020-2025 (%)

7.2 Geographic comparison

Exhibit 24: Geographic comparison

7.3 North America - Market size and forecast 2020-2025

Exhibit 25: North America - Market size and forecast 2020-2025 ($ million)

Exhibit 26: North America - Year-over-year growth 2020-2025 (%)

7.4 Europe - Market size and forecast 2020-2025

Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million)

Exhibit 28: Europe - Year-over-year growth 2020-2025 (%)

7.5 Asia - Market size and forecast 2020-2025

Exhibit 29: Asia - Market size and forecast 2020-2025 ($ million)

Exhibit 30: Asia - Year-over-year growth 2020-2025 (%)

7.6 ROW - Market size and forecast 2020-2025

Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million)

Exhibit 32: ROW - Year-over-year growth 2020-2025 (%)

7.7 Key leading countries

Exhibit 33: Key leading countries

7.8 Market opportunity by geography

Exhibit 34: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

8.1 Market drivers

8.2 Market challenges

Exhibit 35: Impact of drivers and challenges

8.3 Market trends

9 Vendor Landscape

9.1 Overview

Exhibit 36: Vendor landscape

9.2 Landscape disruption

Exhibit 37: Landscape disruption

Exhibit 38: Industry risks

9.3 Competitive scenario

10 Vendor Analysis

10.1 Vendors covered

Exhibit 39: Vendors covered

10.2 Market positioning of vendors

Exhibit 40: Market positioning of vendors

10.3 ANGLE Plc

Exhibit 41: ANGLE Plc - Overview

Exhibit 42: ANGLE Plc - Product and service

Exhibit 43: ANGLE Plc - Key offerings

10.4 Bio Techne Corp.

Exhibit 44: Bio Techne Corp. - Overview

Exhibit 45: Bio Techne Corp. - Business segments

Exhibit 46: Bio Techne Corp. – Key news

Exhibit 47: Bio Techne Corp. - Key offerings

Exhibit 48: Bio Techne Corp. - Segment focus

10.5 Biocept Inc.

10.6 CIRCULOGENE

Exhibit 53: CIRCULOGENE - Overview

Exhibit 54: CIRCULOGENE - Product and service

Exhibit 55: CIRCULOGENE - Key offerings

10.7 F. Hoffmann-La Roche Ltd.

Exhibit 56: F. Hoffmann-La Roche Ltd. - Overview

Exhibit 57: F. Hoffmann-La Roche Ltd. - Business segments

Exhibit 58: F. Hoffmann-La Roche Ltd. – Key news

Exhibit 59: F. Hoffmann-La Roche Ltd. - Key offerings

Exhibit 60: F. Hoffmann-La Roche Ltd. - Segment focus

10.8 Guardant Health Inc.

Exhibit 61: Guardant Health Inc. - Overview

Exhibit 62: Guardant Health Inc. - Business segments

Exhibit 63: Guardant Health Inc. – Key news

Exhibit 64: Guardant Health Inc. - Key offerings

10.9 LungLife AI Inc.

Exhibit 65: LungLife AI Inc. - Overview

Exhibit 66: LungLife AI Inc. - Product and service

Exhibit 67: LungLife AI Inc. - Key offerings

10.10 Myriad Genetics Inc.

Exhibit 68: Myriad Genetics Inc. - Overview

Exhibit 69: Myriad Genetics Inc. - Business segments

Exhibit 70: Myriad Genetics Inc. - Key news

Exhibit 71: Myriad Genetics Inc. - Key offerings

Exhibit 72: Myriad Genetics Inc. - Segment focus

10.11 QIAGEN NV

Exhibit 73: QIAGEN NV - Overview

Exhibit 74: QIAGEN NV - Business segments

Exhibit 75: QIAGEN NV– Key news

Exhibit 76: QIAGEN NV - Key offerings

Exhibit 77: QIAGEN NV - Segment focus

10.12 SAGA Diagnostics AB

Exhibit 78: SAGA Diagnostics AB - Overview

Exhibit 79: SAGA Diagnostics AB - Product and service

Exhibit 80: SAGA Diagnostics AB – Key news

Exhibit 81: SAGA Diagnostics AB - Key offerings

11 Appendix

11.1 Scope of the report

11.2 Currency conversion rates for US$

Exhibit 82: Currency conversion rates for US$

11.3 Research methodology

Exhibit 83: Research Methodology

Exhibit 84: Validation techniques employed for market sizing

Exhibit 85: Information sources

11.4 List of abbreviations

Exhibit 86: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com/

SOURCE Technavio